Register Login

Moleculin Biotech Inc. (MBRX)

(90% Positive) Moleculin Biotech Inc. (MBRX) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8 p.m.

    📋 Moleculin Biotech Inc. (MBRX) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:36:11

    Event Type: Clinical Trial Update

    Event Details:

    Moleculin Biotech Inc. (MBRX) Announces Clinical Trial Update Moleculin Biotech Inc. (MBRX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: trial, used
    • Clinical Stage: Pivotal Trial, pivotal trial
    • Collaboration: AML
    • Updated Timeline: Q1 2026
      • expected in Q3 2026
      • targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122
      • targeting hard-to-treat tumors and viruses, today provided a business outlook and outlined expected upcoming milestones for its next generation non-cardiotoxic anthracycline Annamycin (also known by its generic name “naxtarubicin”) and its STAT3 inhibitor WP1066

    🔬 Clinical Development Pipeline (Moleculin Biotech Inc.):

    Product Type Development Stage Therapeutic Area Source
    Radiation Therapy RADIATION Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    Placebo in combination with Cytarabine Injection DRUG Phase PHASE2 Acute Myeloid Leukaemia (AML) ClinicalTrials.gov
    WP1122 DRUG Phase PHASE1 Healthy Volunteer ClinicalTrials.gov
    Surgical Procedure PROCEDURE Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    STAT3 Inhibitor WP1066 DRUG Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    Magnetic Resonance Imaging PROCEDURE Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    Biospecimen Collection PROCEDURE Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    Liposomal Annamycin for Injection in combination with Cytarabine Injection. DRUG Phase PHASE2 Acute Myeloid Leukaemia (AML) ClinicalTrials.gov
    Liposomal Annamycin Injection in combination with Cytarabine Injection DRUG Phase PHASE2 Acute Myeloid Leukaemia (AML) ClinicalTrials.gov
    Cytarabine DRUG Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    Liposomal Annamycin DRUG Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    WP1220 DRUG Phase PHASE1 Cutaneous T-Cell Lymphoma/Mycosis Fungoides ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Healthy Volunteer ClinicalTrials.gov
    Liposomal Annamycin (L-Annamycin) DRUG Phase PHASE1 Sarcoma,Soft Tissue ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Moleculin Biotech Inc.
    • Ticker Symbol: MBRX

Search

News categories